Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia

Jonathan Canaani, Avraham Frisch, Daniel A. Pollyea, Marc Schwartz, Shlomzion Aumann, Chezi Ganzel, Arnon Haran, Noa Gross Even-Zohar, Adir Shaulov, Vladimir Vainstein, Yakir Moshe, Yishai Ofran, Ofir Wolach, Boaz Nachmias*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objectives: Dysregulation of BCL-2 family members has been reported in acute lymphocytic leukemia (ALL), with various BH3-dependencies of the leukemic clone. We conducted a multicenter retrospective cohort of patients with relapsed/refractory B or T ALL, with ven-chemotherapy or ven-navitoclax combinations, to assess efficacy and safety. Methods: Seventeen patients were included in the analysis, median age was 32 years, with 6 B-ALL and 11 T-ALL patients. Nine patients received venetoclax combined with chemotherapy, and 13 patients received venetoclax in combination with navitoclax, vincristine and asparaginase, of which 5 were already exposed to venetoclax in previous lines. Results: ORR was 55% and 46% among the ven-chemotherapy and the ven-navitoclax-chemotherapy, respectively. Most of the responders proceeded to an allogenic bone marrow transplant in both cohorts. The most common adverse effects of the ven-navitoclax combination were infectious complications and hepatotoxicity. Conclusions: Our data demonstrated the possible efficacy of ven-chemotherapy and ven-navitoclax in r/r ALL with moderate toxicity.

Original languageEnglish
Pages (from-to)365-372
Number of pages8
JournalEuropean Journal of Haematology
Issue number3
StatePublished - Sep 2023


  • acute lymphoblastic leukemia
  • survival
  • venetoclax


Dive into the research topics of 'Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this